The Invesco Perpetual High Income Fund aims to achieve a high level of income, together with capital growth. The fund intends to invest primarily in companies listed in the UK, with the balance invested internationally.
Name | % Net Assets |
---|---|
GlaxoSmithKline | 8.1% |
AstraZeneca | 7.5% |
British American Tobacco | 5.8% |
Reynolds American | 5.6% |
Roche | 4.8% |
Vodafone | 4.8% |
BG | 4.8% |
BT | 4.7% |
Reckitt Benckiser | 4.5% |
BAE Systems | 3.8% |
Key | % Net Assets |
---|---|
GlaxoSmithKline | 8.1% |
AstraZeneca | 7.5% |
British American Tobacco | 5.8% |
Reynolds American | 5.6% |
Other | 73% |
Date | 21-Nov-2024 |
---|---|
NAV | 860.52p |
Currency | GBP |
Change | 1.78p |
% | 0.21% |
YTD change | 71.86p |
YTD % | 9.11% |
Fund Inception | 06/02/1988 |
---|---|
Fund Manager | Neil Woodford |
TER | 1.69 (31-Dec-2013) |
Minimum Investment | |
---|---|
Initial | £500 |
Additional | £100 |
Savings | £20 |
Charges | |
---|---|
Initial | 5.00% |
Annual Mang't | 1.67% |
Exit | n/a |
Name | % |
---|---|
Standard deviation | 0.01 |
Sharpe ratio | 0.22 |
You are here: research